Cleveland Biolabs INC: insider trades · United States · SEC (Form 4)

About Cleveland Biolabs INC

Cleveland BioLabs Inc. is a U.S. biopharmaceutical company historically associated with the NASDAQ market in the United States. The company was incorporated in June 2003 and was headquartered in Buffalo, New York, United States. Its business model centered on developing immune-modulating therapies for high-unmet-need medical settings, with a particular emphasis on radiation injury mitigation and immuno-oncology. The core scientific concept behind the company was a proprietary platform of Toll-like receptor (TLR) activators designed to stimulate innate immune pathways rather than rely solely on conventional targeted oncology approaches. Its most advanced product candidate was Entolimod, a TLR5 agonist studied as a medical countermeasure for exposure to potentially lethal radiation, as well as for additional applications in radiation oncology. Historically, Cleveland BioLabs operated in the United States and Russia through several subsidiaries and collaborative entities, including BioLab 612 and Panacela Labs, and it also had exposure to joint ventures and technology-sharing structures such as Incuron and Genome Protection Inc. From a competitive standpoint, the company occupied a highly specialized niche at the intersection of biodefense, immuno-oncology, and medical countermeasures. In this segment, differentiation depends less on scale and more on intellectual property, translational data, regulatory optionality, and institutional partnerships. For investors, Cleveland BioLabs should be viewed as a small-cap, research-intensive biotech with the typical risk profile of a precommercial platform company: long development cycles, capital dependence, and high execution risk. Recent milestones materially changed the company’s profile. In 2021, Cleveland BioLabs merged with Cytocom and changed its corporate name to Statera Biopharma, and Entolimod was later licensed out to another company. As a result, the “Cleveland BioLabs” name today is primarily relevant from a historical, SEC-reporting, and insider-transaction perspective rather than as a standalone operating biotech under that original identity. In practical terms, this means the company’s legacy is tied to its TLR-based immunotherapy platform and radiation-countermeasure program, while its later corporate evolution has reshaped how investors should interpret older filings and Form 4 insider activity. Overall, it was a U.S.-based biotech story built around immune activation, radiation protection, and oncology applications, with an institutional footprint that has since been transformed.